LATEST NEWS
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
Identifying The Opportunity
KEY LEVELS
Key Level #1 - $5.18
Key Level #2 - $7.54
Key Level #3 - $10.47
Support: $2.75
NeuroSense Therapeutics Ltd.
Multi-Pathway Combination Therapy
- NeuroSense's approach is built on the thesis that complex neurodegenerative diseases like ALS require therapies that address several disease pathways at once.
- PrimeC combines two FDA-approved drugs, ciprofloxacin and celecoxib, in a proprietary extended-release oral formulation, and the company references the FDA 505(b)(2) pathway for this drug repurposing approach.
- The company reported that PrimeC achieved a statistically significant reduction in extracellular vesicle-associated TDP-43 versus placebo, the biomarker primary endpoint of the Phase 2b PARADIGM trial.
- The company's pipeline extends beyond ALS through:
- PrimeC (RoAD) → Phase 2 proof-of-concept in Alzheimer's disease
- StabiliC → preclinical program in Parkinson's disease
- Patents covering PrimeC, including a U.S. composition patent expiring in December 2042, support long-term protection for the formulation.
Regulatory Progress and Next Steps
- NeuroSense is advancing PrimeC toward potential approval in Canada, with a New Drug Submission to Health Canada targeted for December 2026.
- In the U.S., the company plans a smaller, shorter Phase 3 PARAGON design and an active-comparator study against edaravone, subject to FDA alignment.
- The company is pursuing non-dilutive funding and evaluating strategic alternatives, including possible business and corporate transactions.
Positioning for Long-Term Growth
- NeuroSense is focused on bringing PrimeC to patients with ALS, starting in Canada under Health Canada's Notice of Compliance with Conditions (NOC/c) early approval pathway.
- The company has completed commercial manufacturing scale-up for a potential Canadian launch and relies on third-party contract manufacturers for raw materials, active ingredients and finished product.
- Future revenue could come from sales of PrimeC, if approved, or from collaborations, licensing and royalties.
Introducing the Leadership Team of NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)
Alon Ben-Noon
Co-Founder, Chief Executive Officer and Board Member
Alon Ben-Noon founded NeuroSense Therapeutics in 2017 and serves as its Chief Executive Officer and a member of its Board of Directors. He started the company after meeting Shay Rishoni, an ALS patient and former CEO of the nonprofit Prize4Life, who joined the company's advisory board. Before NeuroSense, Mr. Ben-Noon founded MediCan Consulting, where he served biotech clients including Mediwound, Chiasma, Teva, Sol-Gel, FutuRx and NeuroDerm. He holds an MBA and a BSc in Industrial Engineering from Ben-Gurion University.
Or Eisenberg
Chief Financial Officer
Or Eisenberg serves as Chief Financial Officer of NeuroSense Therapeutics.
In the first half of 2026, NeuroSense reduced its operating loss to $3.4 million from $4.7 million in the prior-year period and raised $2.1 million in net proceeds through the issuance of shares.
We get our information from SEC filings and verified public sources.
Stay Ahead. Stay Informed. Stay Profitable.
Subscribe to See What They're Watching
Sources
https://www.sec.gov/ (NRSN SEC Filings: Form 20-F FY2025 and Form 6-K Reports)https://jamanetwork.com/journals/jamaneurology (PARADIGM Results, March 2026)https://www.massgeneralbrigham.org/ (PARADIGM Press Release)https://www.tradingview.com/symbols/NASDAQ-NRSN/
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Pursuant to an agreement between Cue Biopharma, Inc. and Virtus Media Group LLC, Virtus Media has been hired to publicly disseminate information about ticker $CUE via digital communications beginning May 14th, 2026 ending August 15th, 2026. Virtus will be paid $270,000 from Preservation Services LLC
